Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Blinatumomab (DB09052)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment